Daratumumab/hyaluronidase - Janssen Biotech
Alternative Names: DARA-PH20; DARA-SC; daratumumab and hyaluronidase-fihj; Daratumumab subcutaneous - Janssen Biotech; DARZALEX FASPRO; DARZALEX SC; DARZALEX-SC; Darzquro; Recombinant human hyaluronidase-based subcutaneous daratumumabLatest Information Update: 15 Jul 2024
At a glance
- Originator Janssen Biotech
- Developer Janssen Research & Development; Johnson & Johnson Innovative Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Phagocyte stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Amyloid light-chain amyloidosis; Multiple myeloma
- Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 31 May 2024 Updated efficacy data from the phase III PERSEUS trial in Multiple myeloma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 18 Apr 2024 Janssen Research & Development completes a phase II clinical trials in Multiple myeloma (Combination therapy) in France, United Kingdom, Spain, Japan, Israel, Czech Republic, Brazil, USA (SC) (NCT03412565)
- 30 Jan 2024 Johnson & Johnson files sBLA for treatment of patient with Multiple myeloma in USA